Brief: TetraLogic and Merck to evaluate birinapant Keytruda combination in solid tumors

Tetralogic Pharmaceuticals

20/04/2015 13:00

April 20 (Reuters) - TetraLogic Pharmaceuticals Corp  TLOG.O : 
 * Tetralogic and Merck to collaborate on the evaluation of birinapant in 
   combination with Keytruda(R) (pembrolizumab) in solid tumors 
 * The companies have formed a joint development committee to collaboratively 
   oversee the conduct of the study 
 * Results from the study will be used to determine the path for further 
   clinical development of the combination 
 * Says co, Merck, will collaborate on initial phase 1 dose-escalation study of 
   birinapant in combination with keytruda 
 * Says study is expected to begin in late 2015 
 
 * Source text for Eikon  ID:nGNXVDHNSa  
 
 * Further company coverage  TLOG.O   
   ((Bengaluru Newsroom; +1 646 223 8780))